Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: Evidence for sequential selection by drug pressure
Authors: Mallika Imwong
Sasithon Pukrittayakamee
Laurent Rénia
Franck Letourneur
Jean Paul Charlieu
Ubolsree Leartsakulpanich
Sornchai Looareesuwan
Nicholas J. White
Georges Snounou
Mahidol University
Thailand National Center for Genetic Engineering and Biotechnology
Universite Paris Descartes
Institut Pasteur, Paris
Centre for Tropical Diseases Vietnam
John Radcliffe Hospital
Keywords: Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-May-2003
Citation: Antimicrobial Agents and Chemotherapy. Vol.47, No.5 (2003), 1514-1521
Abstract: Mutations in the dihydrofolate reductase (dhfr) genes of Plasmodium falciparum and P. vivax are associated with resistance to the antifolate antimalarial drugs. P. vivax dhfr sequences were obtained from 55 P. vivax isolates (isolates Belem and Sal 1, which are established lines originating from Latin America, and isolates from patient samples from Thailand [n = 44], India [n = 5], Iran [n = 2], and Madagascar [n = 2]) by direct sequencing of both strands of the purified PCR product and were compared to the P. vivax dhfr sequence from a P. vivax parasite isolated in Pakistan (isolate ARI/Pakistan), considered to represent the wild-type sequence. In total, 144 P. vivax dhfr mutations were found at only 12 positions, of which 4 have not been described previously. An F → L mutation at residue 57 had been observed previously, but a novel codon (TTA) resulted in a mutation in seven of the nine mutated variant sequences. A new mutation at residue 117 resulted in S → T (S → N has been described previously). These two variants are the same as those observed in the P. falciparum dhfr gene at residue 108, where they are associated with different levels of antifolate resistance. Two novel mutations, I → L at residue 13 and T → M at residue 61, appear to be unique to P. vivax. The clinical, epidemiological, and sequence data suggest a sequential pathway for the acquisition of the P. vivax dhfr mutations. Mutations at residues 117 and 58 arise first when drug pressure is applied. Highly mutated genes carry the S → T rather than the S → N mutation at residue 117. Mutations at residues 57 and 61 then occur, followed by a fifth mutation at residue 13.
ISSN: 00664804
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.